Abstract
In two clinical trials the mouse antiidiotypic monoclonal antibody (MAb) MF11-30,
which bears the internal image of human
high-molecular-weight-melanoma-associated antigen (HMW-MAA) was administered by
subcutaneous route without adjuvants to patients with stage IV malignant
melanoma on day 0, 7, and 28. Additional injections were administered if
anti-antiidiotypic antibodies were not found or their titer decreased. In the
first phase I trial with 16 patients the initial dose was 0.5 mg per injection
and escalated to 4 mg per injection. Neither toxicity nor allergic reactions
were observed despite the development of anti-mouse Ig antibodies. Minor
responses were observed in three patients. In a second clinical trial MAb
MF11-30 was administered to 21 patients at a dose of 2 mg per injection, since
this dose had been shown in the initial study to be effective in inducing
anti-antiidiotypic antibodies. Two patients were inevaluable; in the remaining
19 patients, the average duration of treatment was 34 wk. In this trial as well,
neither toxicity nor allergic reactions were observed. 17 of the 19 immunized
patients increased the levels of anti-mouse Ig antibodies and 16 developed
antibodies that inhibit the binding of antiidiotypic MAb MF11-30 to the
immunizing anti-HMW-MAA MAb 225.28. One patient increased the level of
anti-HMW-MAA antibodies. One patient achieved a complete remission with
disappearance of multiple abdominal lymph nodes for a duration of 95 wk. Minor
responses were observed in three patients. These results suggest that mouse
antiidiotypic MAb that bear the internal image of HMW-MAA may be useful reagents
to implement active specific immunotherapy in patients with melanoma.
Authors
A Mittelman, Z J Chen, T Kageshita, H Yang, M Yamada, P Baskind, N Goldberg, C Puccio, T Ahmed, Z Arlin
×
Download this citation for these citation managers:
Or, download this citation in these formats:
If you experience problems using these citation formats, send us feedback.